NCT07217158View on ClinicalTrials.gov

Role of ROS and cAMP-PKA Biomarkers in ADPKD

Active, not recruitingOBSERVATIONAL
Enrollment

100

Participants

Timeline

Start Date

July 1, 2023

Primary Completion Date

March 31, 2027

Study Completion Date

June 30, 2027

Conditions
Autosomal Dominant Polycystic Kidney Disease
Trial Locations (1)

55905

Mayo Clinic, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

United States Department of Defense

FED

lead

Mayo Clinic

OTHER

NCT07217158 - Role of ROS and cAMP-PKA Biomarkers in ADPKD | Biotech Hunter | Biotech Hunter